Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse model of gastric cancer. Our hydrophilic monodisperse polysarcosine-based ADC platform has the ability to increase drug-loading (drug-antibody ratios at or above 8) while improving PK profiles, efficacy and tolerability of the conjugates.
About the Next Generation Bioconjugates Summit:
Informa Connect’s Annual Next Generation Protein Therapeutics & Bioconjugates Summit is the industry’s most innovative and comprehensive conference for sharing best practices and new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics to create differentiated drugs. To learn more about the event, please visit the Next Generation Protein Therapeutics & Bioconjugates Summit website here.